Histone Deacetylase Inhibitors, Combination Therapies and Methods of Use

The invention relates to histone deacetylase (HDAC) inhibitors to treat proliferative diseases. The present invention provides novel class III histone deacetylase inhibitors, in particular SIRT1 inhibitors, to reverse the silencing of hypermethylated genes, in combination with one or more other agents, in proliferative diseases such as cancer. The present invention provides methods of activating genes that are silenced by methylation in a subject by administering a HDAC inhibitor in combination with one or more agents.

Patents:
US 20,110,104,177

Inventor(s): BAYLIN STEPHEN [US]; PRUITT KEVIN [US]

Type of Offer: Licensing



« More Medical Patents

---